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Background: Juvenile idiopathic arthritis (JIA), similarly to other arthritides, can be associated with damage of
endothelial layer of which structure and function is dependent on reparative properties of endothelial progenitor
cells (EPC). To date, it remained unknown whether EPC numbers are altered in young JIA patients and whether
on-going anti-inflammatory therapies could exert positive effects on these progenitor cells.
Methods: We performed a quantitative analysis of EPC numbers in 25 patients diagnosed with JIA according to
International League of Associations for Rheumatism (ILAR) criteria [age 11.50 (7.50-15.00) years] in a broad context
of inflammatory and cardiovascular parameters as well as different types of anti-inflammatory treatments. 11 healthy
children [age 13.00 (11.00-14.00) years] were recruited as a control group.
Results: We demonstrated that EPC numbers were similar in JIA patients and control subjects (0.02% vs. 0.05%,
respectively, p = 0.37). EPC levels in JIA patients were negatively correlated with index of insulin resistance
(rho = -0.458, p = 0.021), endogenous insulin (rho = -0.472, p = 0.017), triglyceride (rho = -0.438, p = 0.029)
and TNF-alpha levels (rho = -0.446, p = 0.026). Notably, glucocorticoid (GC) therapy, was associated with detection of
decreased EPC levels in JIA patients (p = 0.023). In contrast, methothrexate (MTX) and etanercept therapy in JIA patients
did not affect EPC levels (p = 0.92 and p = 0.08, respectively).
Conclusions: We found that EPC numbers are maintained at normal levels in JIA patients and are not enhanced by
disease-specific anti-inflammatory treatments.
Keywords: Endothelial progenitor cells, Juvenile idiopathic arthritis, Cardiovascular risk factors, Anti-inflammatory
therapiesBackground
Rheumatoid arthritis (RA) is chronic inflammatory
disease that is associated with significantly increased risk
of development of cardiovascular diseases (CVD) [1].
Patients with RA suffer from 2-5-fold higher morbidity
and mortality related to CVD which in turn leads to
the shortened (by 5-10 years) life expectancy [2].* Correspondence: Marcin.Moniuszko@umb.edu.pl
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unless otherwise stated.Development of CVD in RA patients is caused by
progressive endothelial dysfunction and damage [3].
Preservation of well-functioning endothelium, its ap-
propriate repair and regeneration is warranted by
continuous supplementation of endothelial progenitor
cells (EPC) [2]. EPC originate from bone marrow,
circulate in peripheral blood and keep responding to
signals initiated by endothelial injury that stimulate
maturation of EPC to new endothelial cells [4]. Thus,
EPC remain a key regulator of vascular maintenance
and repair [2,3,5,6]. Indeed, decreased numbers and/or
impaired function of EPCs in adult RA patients were as-
sociated with significant endothelial dysfunction leadinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[6-8]. However, studies on quantification of circulating
EPC numbers brought controversial results as several
groups reported either enhanced or unaltered EPC levels
in adult RA patients [9-11].
In contrast to RA, much less is known about the role
of EPC in the pathogenesis of juvenile idiopathic arth-
ritis (JIA) associated with cardiovascular system injury.
JIA is the most frequently occurring rheumatic disease
in children [12,13]. Despite early onset of disease, JIA
was characterized by development of vascular damage
early in childhood long before establishment of diagnosis
of clinically apparent cardiovascular diseases [12]. Simi-
larly to RA, we recently have demonstrated an increased
cardiovascular risk in JIA patients [14]. Accordingly,
Coulson et al. proposed that long-term risk of develop-
ment of CVD in JIA patients could be even higher
than in other adult-onset inflammatory arthritides [12].
Therefore, the studies on therapies aiming at decreasing
CVD risk in JIA patients are still warranted. Decrease in
CVD risk could be achieved by improvement of endo-
thelial layer structure and function which, in turn, is
dependent on reparative properties of EPC [4,15]. Re-
cently, we found that elevated frequencies of EPC in
type 1 diabetes children correlated inversely with pa-
rameters of endothelial function [16]. Physiologically,
children have significantly higher level of endothelial
progenitor cells than older individuals [17]. To date,
it remained unknown whether numbers of EPC could
be altered in young JIA patients.
In the current study we performed analysis of EPC in
samples derived from these patients as we wished to in-
vestigate putative changes in EPC numbers in the course
of JIA. We aimed to identify potential inflammatory and
cardiovascular parameters that could be related to these
changes. Finally, we set out to analyse whether adminis-
tration of anti-inflammatory treatment could result in




We recruited 25 children, 12 (48%) girls and 13 (52%)
boys, aged 11.50 (7.50-15.00) years, diagnosed with
juvenile idiopathic arthritis (according to International
League of Associations for Rheumatism criteria) for at
least one year; they were followed at the tertiary aca-
demic center, Medical University of Bialystok, Poland.
Oligoarticular and polyarticular types of JIA were re-
ported in 14 (56%) and 11 (44%) patients respectively.
No child had been recognized with systemic type of
the disease. Children were divided into clinically active
(n = 13 – 54%) and inactive (n = 11 - 46%) based on
current practice recommendations [18]. The recruitmentfor the study group, all clinical examinations and qualifica-
tion to the groups were performed by an experienced
pediatric rheumatologist (ED). The control group included
healthy normal-weight boys (n = 4) and girls (n = 7)
aged 13.00 (11.00-14.00) years with blood pressure
below 90th percentile according to reference, negative
family history of CVD and absence of systemic inflam-
matory disease based on physical and laboratory exam-
ination. All children underwent physical examination,
height and weight were taken in a standard way using
Harpenden stadiometer and digital scale (Seca, Germany).
Body mass index (BMI) was calculated with a standard for-
mula. Overweight was determined when the BMI (kg/m2)
exceeded the 85th centile whereas obesity as BMI exceed-
ing the 95th centile according to national growth references
[19]. Because the BMI is not normally distributed in child-
hood, we used the least mean square method, which nor-
malizes the BMI skewed distribution and expresses BMI as
an standard deviation score (SDS-BMI). Systolic (SBP) and
diastolic (DBP) blood pressures were measured twice at
the right arm after a 10-minute rest using calibrated sphyg-
momanometer with appropriate cuff size, and were aver-
aged. We obtained approval of the Ethical Committee
in the Medical University of Bialystok. Both parents/
legal guardians and children gave their written informed
consent.
Laboratory investigations
Blood sample of 10 mL was taken from the left cubital
vein, after an overnight (8-12 hr) fast. To assess inflam-
matory markers serum samples were collected, frozen
and stored at the temperature of -80°C until analyses
were performed. The concentrations of adiponectin,
fractalkine, VE-kadherin, sICAM-1, sVCAM-1, sE-
selectin, MMP-2, MMP-9, TIMP-1, osteoprotegerin
and interleukins: IL-6, IL-18, TNF-alpha were deter-
mined with the use of commercially available ELISA kits
(Parameter Human Immunoassays, R&D Systems, Inc.,
Minneapolis, USA) with the use of ELx 800 Automated
Microplate Reader, Bio-Tek Instruments, Vermont, USA.
hsCRP was determined with use of immunoturbidy-
metric method (Tina-quant hsCRP (Latex) HS, Roche;
Hitachi 912, La Roche, Japan). Concentrations of lipid,
glucose and insulin were determined by standard enzym-
atic methods (Hitachi 912, La Roche, Japan). LDL con-
centration was assessed by the Friedewald equation. The
homeostasis model was used to assess insulin resistance
(HOMA IR) derived from the following formula: insulin
resistance (HOMA IR) = (fasting insulin (mU/ml) x fasting
glucose (mmol/l))/22.5.
Flow cytometry analysis
For quantification of EPC, fresh EDTA-anticoagulated
whole-blood samples were collected. 110 μl of peripheral
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temperature) with 20 μl of anti-human CD34 FITC (BD
Pharmingen) and 5 μl of anti-human CD309 (VEGFR-2)
PE (BD Pharmingen) monoclonal antibodies. Afterwards
samples were lysed with BD FACS Lysing Solution (BD
Bioscences), washed twice with PBS and fixed with use
of CellFix (BD Biosciences) according to manufacturer’s
procedure. Cells were analyzed by FACS Calibur flow cyt-
ometer and CellQuest Software (both from BD Immuno-
cytometry Systems). Positive events gates was set via
FMO (fluorescence-minus-one) controls. Based on posi-
tive surface expression of CD34 EPC were characterized
as CD34+ CD309+ (CD34+ VEGFR-2+) cells localized in
mononuclear cells (MNCs) gates and shown as percent-
ages of total MNCs.
Ultrasonographic imagining
Examinations of the carotid and brachial arteries were
performed with Hewlett Packard Sonos 4500 apparatus,
using a 7.5 MHz linear transducer. The procedure was
conducted between 8.00-10.00 AM after 8-12 hours
fasting. Measurements of intima-media thickness (IMT)
in the common carotid arteries (right and left) were per-
formed as previously described, with own modification
[20]. Measurements included end-diastolic (minimum
diameter) IMT of the far walls, at the distance of more
than 1 cm from the bifurcation. Analyses included the
mean value of 6 measurements.
Ultrasound examination of the right brachial arteries
was performed in longitudinal sections 2-10 cm above
the elbow, according to guidelines [21]. The principle is
to induce vasodilatation in the proximal (brachial) artery
by post-ischemic (forearm) enhanced flow. All lumen
diameter measurements were scanned at end diastole by
use of the R-wave of the electrocardiogram. First scans
were taken at rest, and second scans during reactive
hyperemia. Increased flow was induced by deflating a
pneumatic tourniquet placed on the right forearm,
inflated to the pressure about 50 mmHg above the
patient’s resting systolic blood pressure for 4.5 min. The
post-ischemic scan was performed 45-120 seconds after
cuff deflation. FMD was derived from the percentage
change of the brachial artery diameter after ischemia of
the forearm from baseline.
Statistical analysis
Statistical analysis was performed with use of GraphPad
Prism 6 (GraphPad Software). D’Agostino & Pearson
omnibus normality test was used to determine normal
distribution of data. Normally distributed samples were
analyzed with unpaired t-test and are presented as mean
± standard deviation (SD). Mann-Whitney test was used
to determine differences in groups do not fitting param-
eterized distribution, data are presented as median withinterquartile range (IQR). To test statistically significant
correlations between variables of interest, Spearman’s
correlation was used. In all tests, level of statistical sig-
nificance was set on p < 0.05.
Results
Patients
Demographic and clinical characteristics of JIA patients
and healthy controls is presented in Table 1. Both groups
were similar with regard to gender, age, body mass,
height, BMI and SDS BMI. For further analysis study
group was divided according to the clinical criteria
(activity, type of disease and treatment).
Frequencies of CD34+ and CD34+ CD309+ EPCs in
juvenile arthritis patients
Frequencies of CD34+ cells were comparable in JIA pa-
tients and control subjects (0.1% [0.06%-0.24%] vs. 0.16%
[0.09%-0.39%], respectively, p = 0.39, Figure 1a). Analo-
gously, frequencies of CD34+ VEGFR-2 (CD309) + cells
were similar in JIA patients and healthy controls (0.02%
[0.007%-0.095%] vs. 0.05% [0.014%-0.13%], respectively,
p = 0.37, Figure 1b). Notably, levels of CD34 + CD309+
cells were not related to either activity or type of disease.
Relationships among CD34+ CD309+ cells in juvenile
arthritis patients with clinical and laboratory risk factors
for cardiovascular diseases
Next, we wished to evaluate correlations among fre-
quencies of CD34+ CD309+ cells and varying risk fac-
tors for CVD development. The majority of CVD risk
factors were not significantly associated with levels of
CD34 + CD309+ cells (Table 2). Interestingly, however,
we demonstrated significant negative correlation between
frequencies of CD34 + CD309+ cells and endogenous
insulin levels (rho = -0.472, p = 0.017) and HOMA
IR (rho = -0.458, p = 0.021). Similar correlation was
found for CD34 + CD309+ cells and levels of triglyc-
erides (rho = -0.438, p = 0.029) and TNF-α (rho = -0.446,
p = 0.026).
Effects of glucocorticoid, etanercept and methotrexate
treatment on EPC levels in JIA patients
Furthermore, we demonstrated that patients with JIA
that were treated with GC demonstrated lower levels
of CD34 + CD309+ cells as compared to patients not
treated with GC (0.015% [0.004%-0.06%] vs. 0.08%
[0.037%-0.18%]; p = 0.023, respectively; Figure 2a). In
some contrast, levels of CD34 + CD309+ cells in JIA
patients treated or not with etancercept were similar
(0.005% [0.002%-0.07%] vs. 0.04% [0.014%-0.11%]; p = 0.08,
respectively; Figure 1b).
Next, we demonstrated that metothrexate therapy in
JIA patients did not affect levels of CD34 + CD309+ cells
Table 1 General characteristics of study group
JIA patients Control group p
Number of patients 25 11
Gender
Boys (n, %) 13 (52%) 4 (36%)
0.48+
Girls (n, %) 12 (48%) 7 (64%)
Age (years) 11.50 (7.50-15.00) 13.00 (11.00-14.00) 0.46^
Body mass (kg) 44.54 ± 18.43 47.23 ± 13.17 0.67*
Height (m) 1.48 ± 0.20 1.59 ± 0.12 0.11*
BMI (kg/m2) 19.40 (16.65-21.10) 18.60 (15.60-20.60) 0.50^
SDS-BMI 0.30 (-0.10-0.85) .0.15 (-0.60-0.48) 0.33^
Insulin (mU/ml) 7.70 (4.00-10.95) 6.60 (3.60-8.70) 0.24^
Total-cholesterol (mg/dl) 162.00 ± 26.23 160.20 ± 26.98 0.85*
LDL-cholesterol (mg/dl) 80.84 ± 16.90 86.64 ± 24.65 0.42*
HDL-cholesterol (mg/dl) 57.40 ± 9.87 56.00 ±11.13 0.71*
Triglycerides (mg/dl) 65.00 (49.50-86.50) 64.00 (47.00-100.00) 0.99^
SBP (mmHg) 112.3 (98.65-125.20) 112.70 (105.70-121.70) 0.93^
DBP (mmHg) 59.98 ± 9.19 68.55 ± 8.75 0.01*
FMT (%) 7.96 ± 3.47 10.37 ± 2.63 0.048*
IMT (mm) 0.48 ± 0.09 0.45 ± 0.05 0.27*
Obesity (n, %) 5 (20%)
Insulin resistance (n, %) 6 (24%)
Dyslipidemia (n, %) 7 (28%)
Age of onset (years) 7.00 (3.50-12.25)
Disease duration (years) 3.76 ± 2.58
Disease activity (n, %)
Clinically active 13 (54%)
Clinically inactive 11 (46%)




Glucocorticoids (GC) 18 (72%)
Etanercept 6 (24%)






+Fisher's exact test. *unpaired t-test. ^Mann-Whitney test.
Results are presented as means ± SD or medians with IQR when appropriate
and numbers (n) and percentages (%) where required.
Figure 1 Frequencies of EPC in JIA patients and healthy
controls. Frequencies of a) CD34+ and b) CD34+ CD309+ EPC in
healthy controls and patients with JIA. Median values are presented
as black, horizontal lines while whiskers represent interquartile
range (IQR).
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for JIA patients with and without MTX, respectively)
(Figure 2c).
Having found that different anti-inflammatory drugs
can exert differential effects on EPC levels, we wished toanalyse whether these effects can be attributed to differ-
ent treatment schemes (Figure 2d). We demonstrated
that lowest CD34 + CD309+ cell levels were found in
these JIA patients who received combination of GC, eta-
nercept and metothrexate (0.0035% [0.0015%-0.019%] vs.
0.05% [0.014%-0.13%]; p = 0.024 for JIA and healthy
subjects, respectively). Interestingly, JIA patients treated
with GC, etanercept and metothrexate presented with
significantly lower EPC levels than patients treated
with metothrexate alone (0.0035% [0.0015%-0.019%] vs.
0.062% [0.038%-0.13%], respectively; p = 0.016) or pa-
tients treated with combination of GC and metothexate
(0.0035% [0.0015%-0.019%] vs. 0.017% [0.011%-0.13%],
respectively; p = 0.029) (Figure 2d).
Discussion
Here we performed a cross-sectional analysis of EPC num-
bers in JIA patients in a broad context of inflammatory
Table 2 Correlations of EPC frequencies in patients with
JIA and cardiovascular diseases development risk factors
Percentage of CD34 + CD309+ cells
Variable n rho p
BMI 25 −0.381 0.061
SDS-BMI 25 −0.223 0.283
SBP 25 −0.231 0.266
DBP 25 −0.257 0.216
FMD 25 0.329 0.108
IMT 25 −0.260 0.210
Glucose 25 0.005 0.983
Insulin 25 −0.472 0.017
HOMA IR 25 −0.458 0.021
Triglicerides 25 −0.438 0.029
Total cholesterol 25 −0.267 0.196
LDL-cholesterol 25 0.301 0.144
HDL-cholesterol 25 0.003 0.990
hsCRP 25 −0.210 0.313
Fractalkine 25 −0.031 0.884
Adiponectin 25 0.145 0.488
VE-kadherin 25 −0.045 0.829
sICAM-1 25 −0.148 0.481
sVCAM-1 25 −0.157 0.454
sE-selectin 25 0.009 0.965
MMP-2 25 0.140 0.505
MMP-9 25 0.135 0.519
TIMP-1 25 0.126 0.548
OSP 25 0.159 0.447
TNF-α 25 −0.446 0.026
IL-18 25 −0.364 0.074
IL-6 25 −0.184 0.380
rho: Spearman's correlation coefficient.
Statistically significant correlations are presented in bold. n: number of patients.
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inflammatory treatment. In clear contrast to studies
performed in adult RA patients, we demonstrated that
EPC numbers in JIA pediatric patients are at similar
levels as compared to healthy children. Our study supple-
ments the data derived from adult patients with arthritis.
Previous studies revealed that adult RA patients at mean
age of 34 years presented with insignificantly decreased
EPC levels [8]. In some contrast, elder RA patients at mean
age of 54 years were found to have significantly decreased
EPC levels that, in addition, were correlated to disease
activity [7]. In our study, however, we did not find relation-
ships between EPC numbers and disease activity. Given
our and other published data, one could hypothesize that
EPC in arthritis patients are preserved only at early stagesof disease and then they are becoming gradually dimin-
ished in the course of following years.
One of hypotheses explaining decreased EPC levels
observed in long-lasting RA patients relates this alter-
ation to enhanced neovascularization taking place in
inflamed joints. Indeed, neovascularization remains a
major culprit accounting for synovial hyperplasia ob-
served in the course of both, RA and JIA [13,22]. Not-
ably, substantial numbers of EPC have been detected in
synovial tissue of RA patients [23]. Therefore, reduced
levels of EPC observed in peripheral blood of adult RA
patients could be related to enhanced angiogenesis in
synovium which in turn stimulates increased migration
of EPC to inflamed joints. This however has to be ac-
companied by an efficient homeostatic regeneration and
recirculation of newly developing EPC. Given our data
showing unaltered EPC levels in pediatric JIA patients
and data demonstrating decreased EPC levels in adult
RA patients, one cannot exclude that in the course of
age the capacity to renew decreasing peripheral pool of
EPC might be diminished.
Chronic systemic inflammation being characteristic
feature of JIA affects efficient regeneration of endothelial
cells of remodelled arteries, which in turn leads to devel-
opment of atherosclerosis and increased risk of CVD. In
the current study we correlated EPC numbers with
parameters associated with increased CVD risk. Quite
surprisingly, we found only few significant correlations
between EPC and CVD risk factors (e.g. endogenous in-
sulin, HOMA IR and TNF-alpha). This finding indicates
that augmentation of pro-inflammatory mediators in JIA
patients does not seem to be as strongly related to
changes in EPC levels as in adult RA patients. Moreover,
we did not find significant relationships among EPC
numbers and parameters of development of atheroscler-
osis, namely FMD and IMT. These data are in contrast
to our recent observations of type 1 diabetes children
with early signs of vascular damage whose EPC numbers
were significantly inversely correlated to FMD [16]. It
also has been shown, that EPC correlate inversely with
cIMT in young patients with long-standing type 1
diabetes [24]. This suggests that interplay between EPC
and vascular damage represents a more complex
phenomenon that could be affected by specific disease-
related factors. Interestingly, however, we found that
EPC levels were negatively related to levels of endogen-
ous insulin and HOMA IR. Both abovementioned pa-
rameters were found to constitute relevant risk factors
for development of CVD [25,26]. Notably, this correl-
ation was found despite the fact that endogenous insulin
levels in JIA patients were comparable to those seen in
healthy controls. However, 24% of JIA patients devel-
oped insulin resistance, which stays in contrary with
control group and may indicate that our data are also in
Figure 2 Frequencies of EPC in JIA patients undergoing anti-inflammatory therapies. Frequencies of CD34 + CD309+ EPC in JIA patients
undergoing a) glucocorticoid (GC), b) etanercept, c) methotrexate (MTX) therapy. d) Summary of the effects of different treatment regimens on
frequencies of CD34 + CD309+ cells. Median values are presented as black, horizontal lines, while whiskers represent IQR. Statistically significant
differences are shown; n/a: not applicable (healthy controls).
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resistance was associated with reduced EPC numbers
in animal model of human normoglycemia [27]. In some
parallel, insulin-like growth factor 1 (IGF-1) was recently
demonstrated to decrease survival of certain subsets of
adult stem cells [28-31]. Our demonstration of negative
relationship among EPC and insulin concentrations
suggests that insulin could exert negative effects on EPC
generation and/or distribution. However, in some con-
trast, Humpert et al. demonstrated that formation of
EPC colony-forming units derived from human PBMCs
was enhanced by IGF-1 receptor-dependent signalling
[32]. Moreover, Zhao et al. reported that moderate but
not higher concentrations of insulin and glucose pro-
moted EPC proliferation [33]. Altogether, it may suggest
that dependent on concentration and microenvironment,
insulin could exert varying effects on levels and function
of circulating EPC.
To date, changes in distribution of EPC in JIA patients
were not evaluated in the context of ongoing therapies.
Current management of JIA is, similarly to RA, based onintroduction of varying regimens based on administra-
tion of anti-inflammatory drugs including methotrexate,
glucocorticoid and anti-TNF-alpha monoclonal anti-
bodies. Again, vast majority of current data on potential
interactions between applied treatment of arthritides
and EPC derive from adult RA patients. Surprisingly, to
date, the interactions between EPC and methotrexate
were not studied in sufficient detail. Grisar et al. re-
ported, that active RA patients treated with MTX
showed similar EPC frequencies to patients did not re-
ceive MTX therapy [7]. Additionally, it has been shown,
that methotrexate may induce apoptosis of EPC derived
from healthy volunteers [8]. However, those in vitro
studies require confirmation, considering impaired func-
tion of EPC in rheumatoid patients, which may affect in-
fluence of methotrexate on EPC numbers. On the other
hand, former studies in RA patients revealed that both
GC and etanercept bear capacity to enhance decreased
EPC levels [34,35]. With regard to GC, the positive ef-
fects on EPC numbers were found only for intermediate,
but not low doses of the drug [34]. In some contrast, in
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any of anti-inflammatory treatments applied in JIA pa-
tients on EPC numbers. Moreover, we demonstrated that
in our group of patients, GC therapy was associated with
decrease in EPC levels. Intriguingly, this effect was most
pronounced in these patients who were treated with
combination of GC, metothrexate and etanercept in
some contrast to patients treated with GC and meto-
threxate. This finding provides another, yet unexplored
example of complex interactions between traditional
anti-inflammatory drugs and biologic response modi-
fiers. One could hypothesize that lack of enhancement
of EPC numbers by etanercept or GC could be related
to the fact that JIA patients managed to preserve sus-
tainable EPC numbers. On the other hand, however, one
cannot exclude that normal levels of EPC observed in
studied JIA patients could have resulted from adminis-
tered anti-inflammatory therapies, and without GC ther-
apy associated with systemic inflammation EPC level in
JIA patients could have been lower. Our present under-
standing of dynamic interactions between pool of circu-
lating EPC and those cells that are attracted to inflamed
joints is very limited. Therefore, demonstration of de-
creased EPC levels in peripheral blood can be also ex-
plained by their migration to inflamed joints. Similarly,
lack of enhancement of circulating EPC in pediatric
patients following anti-inflammatory treatment could be
a result of accerelated distribution of these cells to in-
flamed synovial tissues. Further studies exploring mutual
relationships between circulating and synovial EPC are
still warranted. Nonetheless, comparative analysis of our
and other studies indicates that similar treatment regi-
mens introduced to patients at different age can exert
differential effects on EPC numbers. In addition, given
our data, future would shed more light on complex
effects of drugs used in JIA on regenerative potential of
JIA patients.Conclusions
Altogether, we demonstrated here that EPC levels are
maintained at normal levels in pediatric JIA patients and
they are not significantly enhanced by on-going anti-
inflammatory therapies.
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